ALLMedicine™ Ankylosing Spondylitis Center
Research & Reviews 3,830 results
https://doi.org/10.1111/1756-185X.14663
International Journal of Rheumatic Diseases; Ak T, Temiz SNY et. al.
Mar 18th, 2023 - This study aimed to show the effectiveness of interleukin (IL)-23 inhibitors in psoriatic arthritis (PsA) at weeks 12 and 24 in a real-world setting. Forty-three patients with active PsA were enrolled in this study. These patients were treated wit...
https://doi.org/10.1016/j.autrev.2023.103312
Autoimmunity Reviews; Konen FF, Möhn N et. al.
Mar 17th, 2023 - More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to di...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018826
BMC Musculoskeletal Disorders; Deng L, Zheng P
Mar 17th, 2023 - This study aimed to investigate the clinical and laboratory as well as radiological features of spondyloarthritis (SpA) patients with thrombocytosis and to explore risk factor for thrombocytosis in SpA patients and to assess the effect of antitumo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009926
Arthritis Research & Therapy; Popova V, Kissling S et. al.
Mar 15th, 2023 - To analyse whether time-varying treatment with tumour necrosis factor inhibitors (TNFi) in radiographic axial spondyloarthritis (r-axSpA) has a differential impact on structural damage progression on different spinal segments (cervical versus lumb...
https://doi.org/10.1002/acr.25111
Arthritis Care & Research; Karmacharya P, Stull C et. al.
Mar 14th, 2023 - To determine the responsiveness to therapy and minimally clinically important improvement (MCII) for patient-reported outcome (PRO) measures in psoriatic arthritis (PsA) and to examine the impact of baseline disease activity on the ability to demo...
Guidelines 11 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.
Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.
Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine
Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.
Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.
Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...
Drugs 1,077 results see all →
Clinicaltrials.gov 392 results
https://clinicaltrials.gov/ct2/show/NCT05507580
Mar 9th, 2023 - Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment...
https://clinicaltrials.gov/ct2/show/NCT03259074
Mar 9th, 2023 - This was a Phase IIIb, multi-center, randomized, partially-blinded, active-controlled, parallel-group design in subjects with AS. The study consisted of a screening period (up to 10 weeks before randomization), a treatment period (104 weeks), and ...
https://clinicaltrials.gov/ct2/show/NCT04436640
Mar 8th, 2023 - The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and...
https://clinicaltrials.gov/ct2/show/NCT05760105
Mar 8th, 2023 - Osteoporosis is a common disease of bone loss. The reduced bone strength predisposes an increased risk for fractures in older individuals. It can affect people from different ethnicity. Many factors increase the risk of osteoporosis, including age...
https://clinicaltrials.gov/ct2/show/NCT03178487
Mar 7th, 2023 - This study includes two periods: a 14-week double-blind placebo-controlled period and a 90-week open-label long-term extension period. Eligible participants were randomly assigned in a 1:1 ratio to receive upadacitinib 15 mg or placebo for 14 week...
News 835 results
https://www.mdedge.com/rheumatology/article/261519/psoriatic-arthritis/commentary-concerning-psa-treatments-and
Vinod Chandran, MBBS, MD, DM, PhD
Mar 1st, 2023 - Vinod Chandran, MBBS, MD, DM, PhD Psoriatic arthritis (PsA) is a heterogeneous disease with clinical manifestations affecting the skin, joints, spine, and periarticular structures, such as the entheses and tendons. The impact of these manifestatio.
https://www.medpagetoday.com/rheumatology/arthritis/103201
Feb 21st, 2023 - Short-term improvements in axial spondyloarthritis (axSpA) symptoms seen with the interleukin-17A blocker ixekizumab (Taltz) persisted and even increased further among clinical trial participants who continued on the drug for 3 years, without any ...
https://www.mdedge.com/rheumatology/article/261203/psoriatic-arthritis/long-term-safety-and-tolerability-upadacitinib-psa
Feb 14th, 2023 - Key clinical point: Upadacitinib demonstrated an acceptable long-term safety profile and was generally well tolerated with no new safety signals in patients with psoriatic arthritis (PsA). Major finding: Overall, patients with PsA receiving 15 mg.
https://www.mdedge.com/rheumatology/article/260852/psoriatic-arthritis/psa-related-uveitis-real-world-data-epidemiology-and
Jan 26th, 2023 - Key clinical point: Uveitis related to psoriatic arthritis (PsA) had a prevalence of approximately 5%, presented as an acute and recurrent disease with anterior and unilateral involvement, and was associated with impaired quality of life and incre.
https://www.mdedge.com/rheumatology/article/260778/rheumatoid-arthritis/tnfi-raises-risk-septic-arthritis-seropositive-ra
Jan 24th, 2023 - Key clinical point: Tumor necrosis factor inhibitors (TNFi) increased the risk for septic arthritis in patients with seropositive rheumatoid arthritis (RA), with higher incidences within 1 year of initiating TNFi. Major finding: Patients with sero.